Unity King

Gaming and Technology Blog

Tag: Genetic Data

  • 23andMe: 15% Opt-Out After Bankruptcy Filing

    23andMe: 15% Opt-Out After Bankruptcy Filing

    Genetic Data Deletion Requests Surge at 23andMe Post-Bankruptcy

    Since filing for bankruptcy, 23andMe has reported a significant increase in customer requests to delete their genetic data. Approximately 15% of its user base has asked the company to remove their information, raising concerns about data privacy and security amidst financial instability.

    Why Are Users Deleting Their Data?

    Several factors may contribute to this surge in data deletion requests. The primary reason is likely increased anxiety about how a bankrupt company might handle sensitive genetic information. Users might fear potential data breaches, sales of data to third parties, or other misuse scenarios. Heightened awareness of data privacy issues, fueled by frequent news about cyberattacks and data leaks, could also be a contributing factor.

    Data Privacy Concerns

    • Data Security Risks: Users worry about the security of their genetic information in a company facing financial challenges.
    • Potential Misuse: Concerns arise regarding the potential sale or unauthorized use of data by the bankrupt entity or its creditors.
    • Loss of Control: Customers want to regain control over their personal information and ensure it is not compromised during bankruptcy proceedings.

    What Happens to Your Data When You Request Deletion?

    When a user requests data deletion from 23andMe, the company is obligated to remove the genetic data from its active databases. However, complete and irreversible deletion can be complex. Here’s what typically happens:

    1. Account Closure: The user’s account is closed, and access to the platform is terminated.
    2. Data Removal: Genetic data and associated personal information are removed from active databases used for research and analysis.
    3. Backup Retention: Copies of the data may be retained in backups for a certain period, primarily for legal and compliance reasons.
    4. Anonymization: In some cases, data may be anonymized and used for research purposes, ensuring it cannot be linked back to the individual.

    Protecting Your Genetic Privacy

    If you are a 23andMe customer concerned about your genetic data, consider these steps:

    • Review Privacy Settings: Regularly check and adjust your privacy settings on the 23andMe platform to control data sharing preferences.
    • Request Data Deletion: If you’re uncomfortable with the company’s data handling practices, request the deletion of your data.
    • Monitor Data Breaches: Stay informed about potential data breaches or security incidents that could affect your information.
  • Regeneron Acquires 23andMe Data for $256M

    Regeneron Acquires 23andMe Data for $256M

    Regeneron Acquires 23andMe Data for $256M

    Regeneron Pharmaceuticals has announced its plan to acquire 23andMe for $256 million, following the latter’s Chapter 11 bankruptcy filing in March 2025. This acquisition includes 23andMe’s Personal Genome Service, Total Health and Research Services, and its extensive biobank containing genetic data from over 15 million customers .23andMe Investors

    🔍 Strategic Acquisition Details

    The deal is expected to close in the third quarter of 2025, pending court and regulatory approvals. Regeneron aims to integrate 23andMe’s genetic data into its drug discovery and development processes, enhancing its capabilities in genomics-driven research . Despite the acquisition, 23andMe’s consumer genome services are set to continue without interruption .Wikipedia

    🔐 Privacy and Data Protection Commitments

    Given the sensitive nature of genetic information, Regeneron has pledged to uphold 23andMe’s existing privacy policies and comply with all applicable data protection laws. The company will work with a court-appointed ombudsman to ensure ethical handling of customer data . This commitment comes in the wake of a significant data breach in 2023 that affected nearly 7 million 23andMe users .ReutersBBC

    📉 23andMe’s Financial Challenges

    Once valued at over $6 billion after its 2021 public debut, 23andMe faced a series of financial setbacks, including a $30 million settlement over the 2023 data breach and substantial debt accumulation. These challenges led to its bankruptcy filing and the subsequent acquisition by Regeneron .The Washington Post

    🔄 Implications for the Biotech Industry

    This acquisition underscores the growing importance of genetic data in pharmaceutical research and drug development. By integrating 23andMe’s vast genetic database, Regeneron positions itself to accelerate the development of personalized treatments and therapies, reflecting a broader industry trend towards precision medicine .

    Regeneron to Acquire 23andMe for $256 Million

    Regeneron Pharmaceuticals to buy 23andMe for $256M - taking control of genetic data of millions

    New York Post

    Regeneron Pharmaceuticals to buy 23andMe for $256M – taking control of genetic data of millions

    TodayInvestor’s Business Daily23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy AuctionTodayMarketWatch23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA privateToday

    The Value of Genetic Data

    Genetic data is becoming an invaluable resource for pharmaceutical companies. By analyzing the genetic makeup of large populations, researchers can identify patterns and correlations that link genes to specific diseases and conditions. This information can then be used to develop targeted therapies that are more effective and have fewer side effects.

    How 23andMe’s Data Enhances Research

    • Large Sample Size: 23andMe has amassed a significant database of genetic information from millions of customers.
    • Diverse Genetic Backgrounds: The data includes a wide range of genetic backgrounds, making it more representative of the global population.
    • Linked Health Information: Many 23andMe customers have also provided detailed health information, creating a valuable dataset for research purposes.

    Regeneron‘s Strategic Move

    Regeneron‘s acquisition of 23andMe’s data is a strategic move that could give the company a competitive edge in the pharmaceutical industry. By leveraging this data, Regeneron can:

    • Identify Novel Drug Targets: Discover new genetic targets for drug development.
    • Accelerate Clinical Trials: Improve the efficiency of clinical trials by identifying patients who are most likely to respond to a particular treatment.
    • Develop Personalized Medicines: Create personalized medicines tailored to an individual’s genetic makeup.